Tel: 1-631-626-9181 (USA)    44-207-097-1828 (Europe)


Official Full Name
breast cancer anti-estrogen resistance 3
Breast tumors are initially dependent on estrogens for growth and progression and can be inhibited by anti-estrogens such as tamoxifen. However, breast cancers progress to become anti-estrogen resistant. Breast cancer anti-estrogen resistance gene 3 was identified in the search for genes involved in the development of estrogen resistance. The gene encodes a component of intracellular signal transduction that causes estrogen-independent proliferation in human breast cancer cells. The protein contains a putative src homology 2 (SH2) domain, a hall mark of cellular tyrosine kinase signaling molecules, and is partly homologous to the cell division cycle protein CDC48.
BCAR3; breast cancer anti-estrogen resistance 3; breast cancer anti-estrogen resistance protein 3; NSP2; SH2D3B; BCAR 3; Novel SH2 containing protein 2; SH2 domain containing protein 3B; Breast cancer anti estrogen resistance 3; Breast cancer anti estrogen resistance protein 3; Breast cancer antiestrogen resistance 3; dJ1033H22.2; dJ1033H22.2 breast cancer anti estrogen resistance 3; dJ1033H22.2 breast cancer antiestrogen resistance 3; KIAA0554; NSP 2; SH2 containing protein Nsp2; OTTHUMP00000011959; OTTHUMP00000011960; OTTHUMP00000011961; OTTHUMP00000011962; novel SH2-containing protein 2; SH2 domain-containing protein 3B; dJ1033H22.2 (breast cancer anti-estrogen resistance 3)

Interested in learning more?

Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.

Request a quote today!